Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma

Summary

This is a prospective, single-center, single-arm clinical study to evaluate the efficacy and safety of maintenance therapy with obinutuzumab for 2 years in patients ≥ 18 years of age with newly diagnosed mature B-cell lymphoma (including follicular lymphoma\[FL\], marginal zone cell lymphoma\[MZL\] , waldenström macroglobulinemia\[WM\], hairy-cell leukemia variant\[HCL-v\]) who achieved ≥ PR after 6 cycles of obinutuzumab in combination with bendamustine.

Timeline

Start

2023-11-30

Primary completion

2024-11-30

Completion

2026-06-30

Drugs

Indications